Intravitreal VEGF inhibitors — preferred agent selection and prior authorization
Customize your policy alerts
Sign up for mediviewcurative Policy MM-PNP-020 alerts
Get alerted when Policy MM-PNP-020 changes without checking for updates manually.
Monitor payer policy activity
Defines preferred anti-VEGF agents (Avastin first-line, then Cimerli/Byooviz after Avastin trial) and prior authorization/medical necessity criteria for intravitreal VEGF inhibitors for specified retinal disorders; applies to Curative Health Plan medical and pharmacy utilization management staff and providers seeking coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met
Curative considers all other indications experimental and investigational.
Continuation Therapy
Continuation Therapy
Concurrent use of more than one VEGF inhibitor in the same eye is considered experimental and investigational.
Curative considers intravitreal Avastin (bevacizumab), Cimerli, and Byooviz medically necessary only for the specified retinal disorders listed in the policy (for example: diabetic macular edema, neovascular [wet] AMD, macular edema following retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization, neovascular glaucoma, retinopathy of prematurity, and polypoidal choroidal vasculopathy). All other indications not explicitly listed are considered experimental and investigational and are not covered.
Concurrent administration of more than one intravitreal VEGF inhibitor in the same eye is considered experimental and investigational. The policy states this combination use is not covered because the safety and effectiveness of using multiple VEGF inhibitors concurrently in a single eye have not been established.
Curative designates lower-cost bevacizumab products (Avastin) and specified biosimilars (Cimerli and Byooviz) as the preferred agents for the listed medically necessary ocular indications. Use of higher-cost agents (examples cited in the policy include Alymsys, Eylea, Lucentis, Mvasi, and other non-preferred agents) for those indications when lower-cost alternatives are appropriate is considered not medically necessary and may be denied. The preferred agent sequence is Avastin first, then Cimerli or Byooviz only after a trial/failure of Avastin.
Provider Actions and Requirements
Prior authorization required for intravitreal VEGF inhibitors
Prior approval is required for intravitreal VEGF inhibitors. Initial approvals are limited to Avastin (bevacizumab), Cimerli, and Byooviz when used for the specified retinal disorders listed in the policy (e.g., DME, neovascular AMD, RVO-associated macular edema, proliferative diabetic retinopathy, CNV including mCNV and listed etiologies, neovascular glaucoma, retinopathy of prematurity, and PCV).
- Submit prior authorization for intravitreal VEGF inhibitor use.
- Initial approval will only be granted for Avastin, Cimerli, or Byooviz for covered retinal indications.
Step therapy: Avastin first; biosimilars after Avastin trial
Follow the preferred-agent step therapy sequence: Avastin (bevacizumab) is the first-line agent. Cimerli and Byooviz (biosimilars for Lucentis) are considered only after a trial or failure of Avastin for Lucentis indications.
- Use Avastin first-line for medically necessary ocular indications.
- Document trial and failure of Avastin before requesting coverage of Cimerli or Byooviz for Lucentis indications.
Document positive clinical response to continue therapy
For continuation of therapy, document that the member has demonstrated a positive clinical response to the VEGF inhibitor (examples include improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or risk of more severe vision loss).
- Provide objective evidence of improvement or stabilization in BCVA or visual field, or documentation showing reduced rate of vision decline.
- Do not request continuation for concurrent use of more than one VEGF inhibitor in the same eye (considered experimental/investigational).
Risk of denial when prescribing non-preferred higher-cost agents
Use of higher-cost, non-preferred anti‑VEGF agents (examples cited: Alymsys, Eylea, Lucentis, Mvasi and others) when lower-cost alternatives Avastin, Cimerli, or Byooviz are appropriate may be considered not medically necessary and can trigger denial of coverage.
- Do not substitute non-preferred agents without documented medical necessity or prior authorization justification.
- Pharmacy and Medical UM departments will treat other agents as non-preferred and may deny coverage if lower-cost preferred agents are appropriate.
Definitions
Background
Intravitreal vascular endothelial growth factor (VEGF) inhibitors are used to treat multiple retinal disorders. Curative recognizes their role in conditions such as diabetic macular edema (DME), neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), proliferative diabetic retinopathy, choroidal neovascularization (including myopic CNV and other etiologies), neovascular glaucoma, retinopathy of prematurity, and polypoidal choroidal vasculopathy. For these listed indications, Curative considers Avastin (bevacizumab), Cimerli, and Byooviz medically necessary and designates Avastin as the preferred first-line agent, with Cimerli and Byooviz as biosimilar alternatives to Lucentis to be used after an Avastin trial when clinically appropriate.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.